FIGURE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

A, Waterfall plot showing best overall response of evaluable patients on trial. Among 30 patients in the dataset, 24 patients were evaluated for best overall response and 6 patients were not evaluated. Among 24 with best overall response, 4 had PR, 15 had SD, and 5 had PD. For these 24 patients, 22 had percent change from baseline tumor size measured. Two patients who had progression due to unequivocal progression in non-target lesions did not have a tumor size measurement. B, Swimmers plot. All 30 patients treated on study are included. PR, SD, PD, death, and ongoing treatment are indicated.